Revela is building machine-learning software that automatically reviews ultrasound images for subtle indicators of endometriosis and delivers a structured report for clinician review. By inserting AI analysis at the earliest stage of the diagnostic pathway, the platform aims to cut the multi-year delay and need for invasive surgery that many patients currently face. Its algorithms are trained on carefully curated, high-quality datasets gathered in collaboration with patients and clinicians. The company positions itself at the intersection of women’s health and medical imaging, targeting a global market of millions affected by endometriosis. Fresh off a £411,000 pre-seed raise, Revela plans to expand its engineering and clinical teams and secure larger training datasets to accelerate product development. The business is pre-revenue and focused on achieving its first commercial product launch.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2025